Sale

Haemorrhagic Stroke Treatment Market

Global Haemorrhagic Stroke Treatment Market Size, Forecast: By Drug Type: Antihypertensive, Anticoagulants, Anticonvulsants, Others; By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Others; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis; Competitive Landscape; 2024-2032

Global Haemorrhagic Stroke Treatment Market Outlook

The global haemorrhagic stroke treatment market is expected to grow at a CAGR of 4.10% during the period 2024-2032. While rates of incidence of haemorrhagic stroke are heterogenous across the globe, Low and Middle Income countries (LMIC) such as those in Asia and Africa have been witnessing an upward trend.

 

haemorrhagic stroke treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Market Likely to be Driven by Cases of Stroke, Especially in Low and Middle Income Countries (LMIC)

While there is significant regional difference in incidence rates of haemorrhagic stroke, highest rates have been observed in LMIC regions such as sub-Saharan Africa and East Asia.

It is estimated that nearly 750,000 strokes take place in the USA every year. During a stroke, one or more regions in the brain may suffer damage, and an individual may experience loss of ability to move to one side of the body depending on the region affected. The damage may be permanent or temporary, and loss of function may be partial or full. Long-term outcome depends on the extent of brain damage, how quickly treatment starts, and several other factors.

Strokes may lead to long-lasting injury, disability, and even death. Early treatment and precautionary measures may decrease brain damage due to stroke. Treatment depends on stroke type (e.g. ischemic or haemorrhagic), the time since the first stroke symptoms appeared, and the individual’s underlying medical issues. Haemorrhage refers to bleeding. Haemorrhagic stroke takes place when blood vessels in the brain rupture or leak, leading to bleeding in or around the brain. It is estimated that nearly twenty percent strokes are haemorrhagic strokes. Damage may quickly occur because of pressure exerted by increasing amounts of blood or due to the blood itself. Blood irritates the brain tissue, and makes it swell. Bleeding around the brain is called subarachnoid haemorrhage (SAH), and is generally caused when an anomalous blood vessel (aneurysm) on the brain’s surface ruptures. Bleeding into the brain is known as intracerebral haemorrhage (ICH), and is generally caused by high blood pressure.

 

Treatments Options for Haemorrhagic Stroke Expected to Drive the Global Haemorrhagic Stroke Treatment Market

Treatment of haemorrhagic stroke depends on the cause of bleeding (e.g. anticoagulant medications, high blood pressure, trauma to the head, blood vessel malformation). Most patients need to be closely monitored in an ICU during and after a haemorrhagic stroke. Care for an individual suffering from haemorrhagic stroke includes identifying the cause of bleeding; regulating blood pressure; and stopping medication that could aggravate bleeding. A ventriculostomy tube is placed in the ventricle to measure pressure in the brain. If the pressure is high, some cerebrospinal fluid may be removed from the ventricle. A ventriculostomy may be employed to drain blood that has accumulated in the brain due to the stroke.

Treatments for haemorrhagic stroke include:

Surgical treatment — Surgery may be carried out to prevent or stop bleeding, or decrease pressure inside the skull. According to severity of stroke and the patient's condition, surgery may be performed within the first forty-eight to seventy-two hours after the haemorrhage; however, it may also be postponed to be done one to two weeks later to let the patient's condition stabilize.

Aneurysm treatment — An aneurysm refers to a blood vessel with a weak spot that protrudes out. If the area ruptures and bleeds, a haemorrhagic stroke could occur.

A clamp could be placed at the aneurysm’s base to prevent bleeding before a stroke or to stop rebleeding. The procedure entails removing a piece of the skull and tracing the aneurysm within the brain tissue; general anesthesia is generally employed and the procedure takes several hours. The piece of skull is replaced after the procedure.

Coil embolization is a procedure less invasive than clipping; it may be performed while the patient is sedated or put to sleep with the help of medicines. A flexible tube (catheter) is inserted into an artery in the groin, guided along blood vessels in the body into the brain vessel with the aneurysm. A minute coil is guided into aneurysm, filling the area with the coil. A blood clot is created within the coil, which blocks blood flow into the aneurysm and prevents it from rupturing again. Other materials may be injected to treat an aneurysm or arteriovenous malformation (AVM). New treatment systems employ stents (flow diverters) that reduce blood flow to the aneurysm.

Arteriovenous malformation treatment — Some AVMs carry a substantial risk of further bleeding. The decision to treat an AVM may depend on many factors, key factors being patient age, AVM location and size, vein abnormalities that drain the malformation, and whether the AVM has bled previously. Treatment could include surgery, radiosurgery, or embolization techniques.

Decompressive craniotomy — This procedure may be decided upon in cases where a patient's life seems threatened by pressure effects of a blood clot in the brain; it entails opening the skull and/or removing the blood. Considerations include size and location of haemorrhage, age and medical condition of patient, and the chances of recovery from the stroke.

 

Global Haemorrhagic Stroke Treatment Market Likely to be Driven by Demand for Medicines Used in Treatment

Medications for haemorrhagic stroke include:

  • Beta Blockers, Alpha Activity.
  • Vasodilators.
  • Anticonvulsants, Other.
  • Anticonvulsants, Hydantoins.
  • Beta Blockers, Beta-1 Selective.
  • Calcium Channel Blockers.
  • Angiotensin Receptor Blockers.
  • Angiotensin-converting Enzyme Inhibitors.

 

Market Segmentation

 

haemorrhagic stroke treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By type, the market is segmented into:

  • Antihypertensive
  • Anticoagulants
  • Anticonvulsants
  • Others

By distribution channel, the market is divided into:

  • Hospitals Pharmacies
  • Retail Pharmacies 
  • Online Pharmacies

By region, the market is classified into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

haemorrhagic stroke treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Industry Players in the Global Haemorrhagic Stroke Treatment Market

The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • B. Braun Melsungen AG
  • Medtronic
  • Bayer AG
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Type
  • Distribution Channel
  • Region
Breakup by Drug Type
  • Antihypertensive
  • Anticoagulants
  • Anticonvulsants
  • Others
Breakup by Distribution Channel
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • B. Braun Melsungen AG
  • Medtronic
  • Bayer AG
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Others

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Haemorrhagic Stroke Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Haemorrhagic Stroke Treatment Historical Market (2018-2023) 
    8.3    Global Haemorrhagic Stroke Treatment Market Forecast (2024-2032)
    8.4    Global Haemorrhagic Stroke Treatment Market by Drug Type
        8.4.1    Antihypertensive
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    Anticoagulants
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)
        8.4.3    Anticonvulsants
            8.4.3.1    Historical Trend (2018-2023)
            8.4.3.2    Forecast Trend (2024-2032)
        8.4.4    Others
    8.5    Global Haemorrhagic Stroke Treatment Market by Distribution Channel
        8.5.1    Hospitals Pharmacies
            8.5.1.1    Historical Trend (2018-2023)
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    Retail Pharmacies 
            8.5.2.1    Historical Trend (2018-2023)
            8.5.2.2    Forecast Trend (2024-2032)
        8.5.3    Online Pharmacies
            8.5.3.1    Historical Trend (2018-2023)
            8.5.3.2    Forecast Trend (2024-2032)    
     8.6    Global Haemorrhagic Stroke Treatment Market by Region
        8.6.1    North America
            8.6.1.1    Historical Trend (2018-2023) 
            8.6.1.2    Forecast Trend (2024-2032)
        8.6.2    Europe
            8.6.2.1    Historical Trend (2018-2023) 
            8.6.2.2    Forecast Trend (2024-2032)
        8.6.3    Asia Pacific
            8.6.3.1    Historical Trend (2018-2023)
            8.6.3.2    Forecast Trend (2024-2032)
        8.6.4    Latin America
            8.6.4.1    Historical Trend (2018-2023) 
            8.6.4.2    Forecast Trend (2024-2032)
        8.6.5    Middle East and Africa
            8.6.5.1    Historical Trend (2018-2023) 
            8.6.5.2    Forecast Trend (2024-2032)
9    North America Haemorrhagic Stroke Treatment Market Analysis
    9.1    United States of America 
        9.1.1    Historical Trend (2018-2023) 
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023) 
        9.2.2    Forecast Trend (2024-2032)
10    Europe Haemorrhagic Stroke Treatment Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023) 
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023) 
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023) 
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023) 
        10.4.2    Forecast Trend (2024-2032)
    10.5    Others
11    Asia Pacific Haemorrhagic Stroke Treatment Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023) 
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023) 
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023) 
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023) 
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Historical Trend (2018-2023) 
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Haemorrhagic Stroke Treatment Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023) 
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023) 
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023) 
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Haemorrhagic Stroke Treatment Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023) 
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023) 
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023) 
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023) 
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    B. Braun Melsungen AG
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    Medtronic
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    Bayer AG
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    Novartis AG
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    Pfizer Inc.
            15.2.5.1    Company Overview
            15.2.5.2    Product Portfolio
            15.2.5.3    Demographic Reach and Achievements
            15.2.5.4    Certifications
        15.2.6    Merck & Co., Inc.
            15.2.6.1    Company Overview
            15.2.6.2    Product Portfolio
            15.2.6.3    Demographic Reach and Achievements
            15.2.6.4    Certifications
        15.2.7    GlaxoSmithKline plc
            15.2.7.1    Company Overview
            15.2.7.2    Product Portfolio
            15.2.7.3    Demographic Reach and Achievements
            15.2.7.4    Certifications
        15.2.8    Others
16    Key Trends and Developments in the Market

 

List of Figures and Tables

1.    Global Haemorrhagic Stroke Treatment Market: Key Industry Highlights, 2018 and 2032
2.    Global Haemorrhagic Stroke Treatment Historical Market: Breakup by Drug Type (USD Million), 2018-2023
3.    Global Haemorrhagic Stroke Treatment Market Forecast: Breakup by Drug Type (USD Million), 2024-2032
4.    Global Haemorrhagic Stroke Treatment Historical Market: Breakup by Distribution Channel (USD Million), 2018-2023
5.    Global Haemorrhagic Stroke Treatment Market Forecast: Breakup by Distribution Channel (USD Million), 2024-2032
6.    Global Haemorrhagic Stroke Treatment Historical Market: Breakup by Region (USD Million), 2018-2023
7.    Global Haemorrhagic Stroke Treatment Market Forecast: Breakup by Region (USD Million), 2024-2032
8.    North America Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
9.    North America Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
10.    Europe Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
11.    Europe Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
12.    Asia Pacific Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
13.    Asia Pacific Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Latin America Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
15.    Latin America Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Middle East and Africa Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
17.    Middle East and Africa Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
18.    Global Haemorrhagic Stroke Treatment Market Structure

Key Questions Answered in the Report

The global haemorrhagic stroke treatment market is projected to grow at a CAGR of 4.10% between 2024 and 2032.

The major drivers of the market include the high diagnostic rate, availability of the treatment options, high demand of diseases specific treatment, rise in adoption of newer technologies, presence of refined healthcare infrastructure, and increased patient awareness level.

The rising incidences of haemorrhagic stroke and increase healthcare spending are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Based on drug type, the market is segmented into antihypertensive, anticoagulants, and anticonvulsants, among others.

The several distribution channels of the market are hospitals pharmacies, retail pharmacies, and online pharmacies.

The major players in the industry are B. Braun Melsungen AG, Medtronic, Bayer AG, Novartis AG, Pfizer Inc., Merck & Co., Inc., and GlaxoSmithKline plc, among others.

Analyst Review

The global haemorrhagic stroke treatment market was driven by the rising incidences of haemorrhagic stroke in the historical period. Aided by the high diagnostic rate and an increase healthcare spending, the market is expected to witness further growth in the forecast period of 2024-2032, growing at a CAGR of 4.10%.

EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on drug type, the market is segmented into antihypertensive, anticoagulants, and anticonvulsants, among others. The several distribution channels of the market are hospitals pharmacies, retail pharmacies, and online pharmacies. The major regional markets for haemorrhagic stroke treatment are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The major players in the industry are B. Braun Melsungen AG, Medtronic, Bayer AG, Novartis AG, Pfizer Inc., Merck & Co., Inc., and GlaxoSmithKline plc, among others.

EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER